Unnamed: 0,title,date,stock,sentiment
241438.0,"Coherus BioSciences Q1 EPS $0.480 Misses $0.560 Estimate, Sales $116.180M Miss $119.520M Estimate",2020-05-07 17:07:00-04:00,CHRS,negative
241439.0,Coherus BioSciences shares are trading higher after SunTrust Robinson Humphrey initiated coverage on the stock with a Buy rating and a price target of $26 per share.,2020-04-17 08:30:00-04:00,CHRS,positive
241440.0,"SunTrust Robinson Humphrey Initiates Coverage On Coherus BioSciences with Buy Rating, Announces Price Target to $26",2020-04-17 07:27:00-04:00,CHRS,neutral
241441.0,"Coherus Warns 'There are reasons to expect that the adverse effects we are experiencing and expect to continue to experience from COVID-19' In Q2, H2'20",2020-04-13 09:26:00-04:00,CHRS,negative
241442.0,"Coherus Reports Pegfilgrastim Class Unit Growth During Last 4 Weeks Of Mar. Up 6% Month Over Month, UDENYCA Unit Growth 7%",2020-04-13 09:25:00-04:00,CHRS,positive
241443.0,"Coherus Biosciences Sees Q1 Sales $115M-$117.5M vs $118.9M Estimate, Net Income $33.5M-$38M",2020-04-13 09:24:00-04:00,CHRS,neutral
241444.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,CHRS,positive
241445.0,"Coherus BioSciences Reports Its US Manufacturing, Distribution Is Well Positioned To Ensure Uninterrupted Availability Of UDENYCA For Patients",2020-03-05 07:22:00-05:00,CHRS,positive
241446.0,"H.C. Wainwright Reiterates Buy on Coherus BioSciences, Raises Price Target to $30",2020-02-28 07:28:00-05:00,CHRS,neutral
241447.0,"Coherus BioSciences Q4 EPS $0.53 Misses $0.72 Estimate, Sales $123.856M Beat $123.01M Estimate",2020-02-27 16:03:00-05:00,CHRS,negative
241448.0,"JP Morgan Maintains Overweight on Coherus BioSciences, Raises Price Target to $35",2020-02-06 08:34:00-05:00,CHRS,neutral
241449.0,"Coherus BioSciences Acquires the Commercial Rights for Avastin in the United States, Will Pay Up to $45M in Milestones",2020-01-13 08:44:00-05:00,CHRS,positive
241450.0,Coherus BioSciences shares are trading higher. The company on Wednesday reported Q3 results and acquired the rights to commercialize Bioeq's biosimilar candidate Lucentis.,2019-11-07 10:42:00-05:00,CHRS,positive
241451.0,"Citigroup Maintains Buy on Coherus BioSciences, Raises Price Target to $31",2019-11-07 07:24:00-05:00,CHRS,neutral
241452.0,"Coherus BioSciences Q3 EPS $0.63 Beats $0.51 Estimate, Sales $111.68M Beat $101.37M Estimate",2019-11-06 16:22:00-05:00,CHRS,neutral
241453.0,Coherus Acquires Rights to Commercialize Bioeq's Biosimilar Canidate to Lucentis in the US for a 'Mid-Single Million Dollar' Upfront Payment,2019-11-06 16:19:00-05:00,CHRS,neutral
241454.0,Coherus BioSciences shares are trading lower. Not seeing any news to justify the price action.,2019-11-05 09:24:00-05:00,CHRS,neutral
241455.0,Coherus BioScience shares are trading lower despite no company specific news. The stock has dropped approximately 23% over the past month.,2019-10-22 12:53:00-04:00,CHRS,positive
241456.0,Coherus BioSciences shares are trading lower. Not seeing any news to justify the price action.,2019-10-09 11:35:00-04:00,CHRS,neutral
241457.0,Coherus Biosciences shares are trading higher. Not seeing any news to justify price action.,2019-10-04 13:17:00-04:00,CHRS,positive
241458.0,"Coherus BioSciences Shares Fall 6% Over Last Min., Still Up 1% for Session",2019-09-25 14:29:00-04:00,CHRS,positive
241459.0,"Mizuho Initiates Coverage On Coherus BioSciences with Buy Rating, Announces $43 Price Target",2019-08-13 07:16:00-04:00,CHRS,neutral
241460.0,Coherus Biosciences Shares Quiet After Hours As Hearing Mizuho Initiated Coverage With A Buy Rating And $43 Price Target,2019-08-12 16:10:00-04:00,CHRS,positive
241461.0,"Coherus BioSciences Late Thursday Reported Q2 EPS $0.32 Beat $0.08 Estimate, Sales $83.433M Beat $75.49M Estimate",2019-08-02 09:49:00-04:00,CHRS,neutral
241462.0,Dismissal of Amgen's Patent Infringement Lawsuit Against Coherus Biosciences is Upheld by the US Appeals Court,2019-07-29 09:19:00-04:00,CHRS,negative
241463.0,Coherus BioSciences Sees Prelim. Q2 UDENYCA Net Sales Of $79M-$84M,2019-07-08 09:31:00-04:00,CHRS,neutral
241464.0,Coherus BioSciences Reports Produced 400K+ UDENYCA Pre-Filled Syringes To Date,2019-07-01 09:31:00-04:00,CHRS,neutral
241465.0,Coherus BioSciences shares are trading higher after Barclays initiated coverage on the company's stock with an overweight rating and a $30 price target.,2019-06-11 09:40:00-04:00,CHRS,negative
241466.0,"Barclays Initiates Coverage On Coherus BioSciences with Overweight Rating, Announces $30 Price Target",2019-06-11 07:04:00-04:00,CHRS,negative
241467.0,"Coherus BioSciences Q1 EPS $(0.29) Beats $(0.46) Estimate, Sales $37.098M Beat $37.05M Estimate",2019-05-09 16:55:00-04:00,CHRS,neutral
241468.0,"H.C. Wainwright Initiates Coverage On Coherus BioSciences, Inc. - Common Stock with Buy Rating, Announces $28 Price Target",2019-05-07 08:32:00-04:00,CHRS,neutral
241469.0,Coherus BioSciences And Amgen Settle Trade Secrets Action,2019-05-02 18:37:00-04:00,CHRS,neutral
241470.0,Coherus BioSciences Reports Settlement Of Trade Secrets Action With Amgen,2019-05-02 18:36:00-04:00,CHRS,neutral
241471.0,"Benzinga Pro's Top 8 Most-Searched Tickers For Morning Of Mon., Apr. 8, 2019",2019-04-08 10:29:00-04:00,CHRS,positive
241472.0,"Coherus Biosciences shares are trading higher after the company said it expects Q1 UDENYCA net sales of $36 million to $38 million, well above the analyst consensus estimate.",2019-04-08 09:39:00-04:00,CHRS,positive
241473.0,"Coherus Biosciences Will Not Disclose Topline Gross Sales, Discounts, Or Gross-To-Net Data Until Reported In Its Form 10-Q For Qtr Ended March 31",2019-04-05 16:18:00-04:00,CHRS,positive
241474.0,Coherus BioSciences Sees Q1 Sales $36M-$38M,2019-04-05 16:06:00-04:00,CHRS,neutral
241475.0,Coherus BioSciences Management To Present At H.C. Wainwright & Co. Global Life Sciences Conference,2019-03-28 09:30:00-04:00,CHRS,neutral
241476.0,Coherus BioSciences Q4 EPS $(0.92) Misses $(0.86) Estimate,2019-02-28 17:18:00-05:00,CHRS,negative
241477.0,Coherus BioSciences Files Patent Infringement Suit Against Amgen Reated To Amgen's Humira Biosimilar,2019-01-25 12:03:00-05:00,CHRS,negative
241478.0,"UPDATE: Coherus Says License Period In US Begins Dec. 15, 2023; Coherus Will Pay Royalties To AbbVie, But Financial Terms Not Disclosed",2019-01-25 08:02:00-05:00,CHRS,negative
241479.0,Coherus BioSciences Reports Global Settlement With AbbVie Which Secures Rights To Commercialize CHS-1420,2019-01-25 08:01:00-05:00,CHRS,positive
241480.0,Coherus Biosciences shares are trading higher after the company secured $75 million of credit financing with HealthCare Royalty Partners.,2019-01-07 11:13:00-05:00,CHRS,positive
241481.0,Coherus BioSciences Secures $75M Credit Financing With HealthCare Royalty Partners,2019-01-07 09:26:00-05:00,CHRS,positive
241482.0,"Coherus BioSciences Announces Apexus Contract Agreement For 340B Hospitals And Clinics, And Q-Code Issuance From CMS",2018-11-30 09:30:00-05:00,CHRS,positive
241483.0,CMS Reportedly Posted New Reimbursement Q-Code (Q5111) For Coherus Biosciences' Udenyca,2018-11-21 15:18:00-05:00,CHRS,neutral
241484.0,Coherus BioSciences shares are trading down 15.9% after it missed Q3 EPS estimates.,2018-11-09 14:00:00-05:00,CHRS,neutral
241485.0,Coherus Biosciences Q3 EPS $(0.87) Misses $(0.77) Estimate,2018-11-08 16:36:00-05:00,CHRS,negative
241486.0,Coherus BioSciences Reports FDA Has Approved UDENYCA,2018-11-02 13:41:00-04:00,CHRS,positive
241487.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,CHRS,neutral
